CS
SRNE

Candriam SCA’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Candriam SCA’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-310,000
Closed -$1.36M – 859
2018
Q3 		$1.36M Hold
310,000
– – 0.02% 569
2018
Q2 		$2.23M Hold
310,000
– – 0.04% 463
2018
Q1 		$1.6M Buy
+310,000
New +$2.21M 0.03% 522

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Candriam SCA's SRNE Position: Q4 2018 in Review

Candriam SCA sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 310,000 shares — an estimated $1.36M sold.

Candriam SCA first reported a position in SRNE in Q1 2018 and held it in 3 quarters. The position peaked at $2.23M in Q2 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

  • Candriam SCA reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Candriam SCA sold 310,000 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $1.36M.
  • Candriam SCA first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and held it in 3 quarters.
  • Candriam SCA's Sorrento Therapeutics, Inc. position peaked at $2.23M in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.